Drug Profile
Research programme: cancer immunotherapy - NCI/Ortho Biotech Oncology Research & Development
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA); Ortho Biotech Oncology Research & Development
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 04 Jun 2009 Preclinical trials in Cancer in USA (unspecified route)